Literature DB >> 12193744

Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells.

Margit H Hansen1, Heidi V Nielsen, Henrik J Ditzel.   

Abstract

Tumor-infiltrating lymphoplasmacytic cells are a key feature of medullary carcinoma of the breast (MCB), a distinct subtype of human breast cancer that, despite cytologically anaplastic characteristics, has a more favorable prognosis than other types of breast cancer. Since it has been proposed that the improved clinical outcome is due at least in part to the presence of a prominent lymphoplasmacytic cell infiltrate in the tumor stroma, we recently examined the tumor-infiltrating B cell response in MCB and showed that it is oligoclonal and directed against an intracellular protein translocated to the cell surface upon MCB cell apoptosis. Human Abs cloned from MCB lymphoplasmacytic infiltrate-derived phage display libraries and reflecting the dominant part of the response were used to identify the target Ag as actin. Here, we have characterized in detail the cloned human IgG Abs and the translocation process of actin to the cell surface of apoptotic MCB cells. Our analysis shows that the cloned Abs bind specifically and with high affinity to actin, as determined by ELISA and surface plasmon resonance. Sequence analysis revealed that the Abs are highly somatically mutated, with high replacement to silent ratios, indicative of an Ag-driven, affinity-matured response. Interestingly, the tumor-infiltrating B cells in half the MCB patients mainly exhibited an IgG2 response, while IgG1 dominated in the others. To gain insight to the molecular events that may elicit such an Ab response, we examined the translocation of actin to the cell surface of apoptotic MCB cells using flow cytometry and laser scanning cytometry. Our results show that actin becomes exposed on the cell surface of a large proportion of apoptotic MCB cells as an early apoptotic event. We propose that the Ab response against actin produced by tumor-infiltrating B lymphoplasmacytic cells is Ag-driven, affinity-matured, and elicited due to the increased rate of apoptosis occurring within the MCB tumor that facilitates the translocation and proteolytic fragmentation of intracellular proteins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12193744     DOI: 10.4049/jimmunol.169.5.2701

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

Review 1.  Serologic laboratory findings in malignancy.

Authors:  Félix Fernández Madrid; Marie-Claire Maroun
Journal:  Rheum Dis Clin North Am       Date:  2011-11       Impact factor: 2.670

Review 2.  B cells, plasma cells and antibody repertoires in the tumour microenvironment.

Authors:  George V Sharonov; Ekaterina O Serebrovskaya; Diana V Yuzhakova; Olga V Britanova; Dmitriy M Chudakov
Journal:  Nat Rev Immunol       Date:  2020-01-27       Impact factor: 53.106

3.  Identification of tumor-associated antigens from medullary breast carcinoma by a modified SEREX approach.

Authors:  Ramziya Kiyamova; Olga Kostianets; Sergey Malyuchik; Valeriy Filonenko; Vasiliy Usenko; Vadym Gurtovyy; Yuliya Khozayenko; Stepan Antonuk; Lloyd Old; Ivan Gout
Journal:  Mol Biotechnol       Date:  2010-10       Impact factor: 2.695

Review 4.  B lymphocytes and cancer: a love-hate relationship.

Authors:  Grace J Yuen; Ezana Demissie; Shiv Pillai
Journal:  Trends Cancer       Date:  2016-12

5.  Tumor-infiltrating B cells come into vogue.

Authors:  Michael Linnebacher
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

6.  Screening of a HUAEC cDNA library identifies actin as a candidate autoantigen associated with carotid atherosclerosis.

Authors:  P Margutti; F Delunardo; M Sorice; G Valesini; C Alessandri; R Capoano; E Profumo; A Siracusano; B Salvati; R Riganò; E Ortona
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

7.  Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer.

Authors:  Michael D Iglesia; Benjamin G Vincent; Joel S Parker; Katherine A Hoadley; Lisa A Carey; Charles M Perou; Jonathan S Serody
Journal:  Clin Cancer Res       Date:  2014-06-10       Impact factor: 12.531

Review 8.  Clinical relevance of host immunity in breast cancer: from TILs to the clinic.

Authors:  Peter Savas; Roberto Salgado; Carsten Denkert; Christos Sotiriou; Phillip K Darcy; Mark J Smyth; Sherene Loi
Journal:  Nat Rev Clin Oncol       Date:  2015-12-15       Impact factor: 66.675

9.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

10.  Tumor-infiltrating B cells: The ignored players in tumor immunology.

Authors:  Michael Linnebacher; Claudia Maletzki
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.